Middle East Low Molecular Weight Heparin Market 2028 By Product, Packaging, Application, End User, Distribution Channel | The Insight Partners

report image

Middle East Low Molecular Weight Heparin Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product ( Enoxaprin, Dalteparin, Tinzaprin, Fraxiparine, Nadroparin, Others ); Packaging ( Multi-vials, Prefilled Syringes ); Application ( Deep Vein Thrombosis, Acute Coronary Syndrome (ACS), Pulmunary Embolism, Others ); End User ( Hospitals, Clinics, Ambulatory Surgical Centers, Others ); Distribution Channel ( Hospital Pharmacies, Retail Pharmacies, Others )

Report Code: TIPRE00029731 | No. of Pages: 150 | Category: Biotechnology | Status: Upcoming

MARKET OVERVIEW

Low-molecular-weight heparins (LMWHs) are a new class of anticoagulants derived from unfractionated heparin (UFH). Low-molecular-weight heparin belong to the group of anticoagulant medications. LMWHs are used in the prevention of blood clots and treatment of myocardial infarction and in the treatment of venous thromboembolism. Heparin is a naturally occurring polysaccharide that inhibits coagulation, the process that leads to thrombosis.

MARKET SCOPE

The "Middle East Low Molecular Weight Heparin Market Analysis to 2028" is a specialized and in-depth examination of the healthcare industry, with a particular emphasis on regional market trend analysis. The purpose of this report is to provide an overview of the low molecular weight heparin market, as well as detailed market segmentation based on product, packaging, application, end user, and distribution channel. Additionally, the report offers key statistics on the market status of the leading low molecular weight heparin market players, as well as key market trends and opportunities.

MARKET SEGMENTATION

  • Based on product, the market is segmented into enoxaparin, dalteparin, tinzaparin, fraxiparine, nadroparin, and others.
  • Based on packaging, the market is bifurcated into multi-vials and prefilled syringes.
  • Based on application, the market is segmented into deep vein thrombosis, acute coronary syndrome (acs), pulmonary embolism, and others.
  • Based on end user, the market is segmented into Hospitals, Clinics, Ambulatory Surgical Centers, and Others.
  • Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and others.

MARKET DYNAMICS

Drivers-

  • Advantages of low molecular weight heparin anticoagulants over unfractionated heparin will drive the market growth.
  • High prevalence of cardiovascular disease in the Middle East countries will fuel the market growth.

Restraint-

  • Adverse effects of low molecular weight heparin such as bleeding disorders and Heparin-induced thrombocytopenia (HIT) hinders the growth of overall market.

REGIONAL FRAMEWORK

The report offers a comprehensive overview of the industry, including both qualitative and quantitative data. It provides a regional market overview and forecast based on various segments. It also provides market size and forecast estimates for countries in Middle East, namely Saudi Arabia, U.A.E., Kuwait, Qatar, Bahrain, Oman, and Rest of Middle East, from 2022 to 2028. The report analyses and forecasts 7 countries, as well as the current trend and opportunities in the region.

The report analyses market factors affecting both the demand and supply sides, as well as market dynamics affecting the market during the forecast period, such as drivers, restraints, opportunities, and future trends. The report also includes a comprehensive PEST analysis for the Middle East after assessing the political, economic, social, and technological factors influencing the low molecular weight heparin market in the region.

Impact of COVID-19 on Middle East Low Molecular Weight Heparin Market

The Middle East have strengthened their health systems, along with upgrading public and commercial healthcare. However, the limited availability of resources, including trained staff and medical equipment; and the burden of noncommunicable diseases harm the overall healthcare system in the region. In 2020, the COVID-19 pandemic had a significant impact on the delivery and accessibility of social services, education, health and nutrition, healthcare spending, and wellbeing- and development-related businesses in the Middle East. As in COVID-19-induced acute respiratory distress syndrome, the lungs could not fill with sufficient air, causing hypoxemia and high mortality among hospitalized patients. Such factors were responsible for accelerating demand for the Middle East low molecular weight heparin market during the forecast period of 2022-2028.



Get more information on this report :

MARKET PLAYERS

The report covers key developments in the Middle East low molecular weight heparin market with focus on two  main strategies such as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies that includes new product launches, product approvals by the authorized bodies, and others such as patents and events. Inorganic growth strategies activities normally  includes strategic acquisitions, and partnership & collaborations between the companies. These activities have paved way for the expansion of business and customer base of market players. The market payers from Middle East low molecular weight heparin market are anticipated to lucrative growth opportunities in the future with the rising demand for low molecular weight heparin in Middle East.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the Middle East low molecular weight heparin market. Also, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, and the key development in the past five years.

  • Abbott
  • Aspen Holdings
  • B. Braun Medical, Inc.
  • Dr. Reddy's Laboratories Limited
  • Hikma Pharmaceuticals PLC
  • Leopharma A/S
  • Novartis AG      
  • Pfizer, Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

The Insight Partner’s dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.



Get more information on this report :

  • Abbott
  • Aspen Holdings
  • B. Braun Medical, Inc.
  • Dr. Reddy's Laboratories Limited
  • Hikma Pharmaceuticals PLC
  • Leopharma A/S
  • Novartis AG      
  • Pfizer, Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
TIPRE00029731
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market




tip-analyst

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak To Analyst
Pricing
  • $2000
  • $3000
  • $4000
  • $5000

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount